Difference between revisions of "Pralsetinib (Gavreto)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== From the [NCI Drug Dictionary]: An orally bioavailable selective inhibitor of mutant forms of and fusion products involving the proto-oncogene receptor...") |
m |
||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
| − | From the | + | From the NCI Drug Dictionary: An orally bioavailable selective inhibitor of mutant forms of and fusion products involving the proto-oncogene receptor tyrosine kinase RET, with potential antineoplastic activity. Upon administration, BLU-667 binds to and targets various RET mutants and RET-containing fusion product. |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Non-small cell lung cancer, RET-positive|RET-positive NSCLC]] | *[[Non-small cell lung cancer, RET-positive|RET-positive NSCLC]] | ||
| + | *[[Thyroid cancer, RET-positive]] | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*9/4/2020: Granted accelerated approval for adult patients with metastatic RET fusion-positive [[non-small cell lung cancer|non-small cell lung cancer (NSCLC)]] | *9/4/2020: Granted accelerated approval for adult patients with metastatic RET fusion-positive [[non-small cell lung cancer|non-small cell lung cancer (NSCLC)]] | ||
| + | *12/1/2020: Approved for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary [[thyroid cancer]] (MTC) who require systemic therapy. | ||
| + | *12/1/2020: Approved for adult and pediatric patients 12 years of age and older with RET fusion-positive [[thyroid cancer]] who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). | ||
==Also known as== | ==Also known as== | ||
| Line 18: | Line 21: | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
| + | [[Category:Thyroid cancer medications]] | ||
| + | |||
[[Category:FDA approved in 2020]] | [[Category:FDA approved in 2020]] | ||
Revision as of 01:58, 2 December 2020
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable selective inhibitor of mutant forms of and fusion products involving the proto-oncogene receptor tyrosine kinase RET, with potential antineoplastic activity. Upon administration, BLU-667 binds to and targets various RET mutants and RET-containing fusion product.
Diseases for which it is used
History of changes in FDA indication
- 9/4/2020: Granted accelerated approval for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC)
- 12/1/2020: Approved for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
- 12/1/2020: Approved for adult and pediatric patients 12 years of age and older with RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
Also known as
- Code name: BLU-667
- Brand name: Gavreto